Sichuan Kelun-Biotech Biopharmaceutical Co Ltd (HK:6990), a holding subsidiary of China-based Kelun Pharmaceutical (SZ:002422), announced on Wednesday that it has received marketing authorisation from China's National Medical Products Administration (NMPA) for its trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC), sacituzumab tirumotecan (sac-TMT, formerly SKB264/MK-2870), for adult patients with unresectable locally advanced or metastatic triple negative breast cancer (TNBC) who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting).
This is the first domestically developed TROP2 ADC approved for marketing in China and the first domestically developed ADC fully approved for marketing in China.
The approval was based on positive results from the randomised, controlled, phase 3 OptiTROP-Breast01 study in adult patients with unresectable locally advanced or metastatic TNBC who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting). Sac-TMT demonstrated statistically significant and clinically meaningful improvement in both progression-free survival (PFS) and overall survival (OS) compared to chemotherapy. The results were presented at the special clinical science symposium for next-generation ADCs at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in May 2024.
Gilead showcases efficacy of twice-yearly lenacapavir for HIV prevention at IAS 2025
Merck announces Phase 3 trials for once-monthly oral HIV prevention pill MK-8527
GSK announces submission of RSV vaccine Arexvy for FDA review
AstraZeneca's Baxdrostat meets all endpoints in pivotal Phase III hypertension trial
IGI and AbbVie enter global licensing agreement for ISB 2001
REGENXBIO reports RGX-202 preclinical results in Duchenne Muscular Dystrophy
MetaVia doses first patient in 48 mg MAD cohort of DA-1726 Phase 1 trial
GenScript Biotech awarded EcoVadis Silver Medal
Zhimeng Biopharma's CB03-154 ALS Phase 2/3 study receives Chinese clinical trial approval
Taiho Oncology and Taiho Pharmaceutical's INQOVI/venetoclax combination sNDA accepted by US FDA
SciBase introduces Nevisense pilot at Florida research university